New Nature Communications Study Highlights MI-883’s Therapeutic Potential in Hypercholesterolemia
February 6, 2025 – A recent publication in Nature Communications presents compelling preclinical evidence supporting MI-883 as a promising therapeutic agent for hypercholesterolemia. The study, titled “The hypolipidemic effect of MI-883, the combined CAR agonist/PXR antagonist, in diet-induced hypercholesterolemia model,” demonstrates that MI-883, a dual-function compound, effectively lowers plasma cholesterol levels and enhances bile acid excretion. https://doi.org/10.1038/s41467-025-56642-y By selectively modulating […]
New CAR-Selective Compounds Show Promise for Liver and Metabolic Disorders
February 3, 2023 – Researchers have discovered a new class of compounds that selectively activate the human constitutive androstane receptor (CAR), offering a potential breakthrough in treating liver and metabolic diseases. https://doi.org/10.1021/acs.jmedchem.2c01140 Published in Journal of Medicinal Chemistry, the study highlights 3-(1H-1,2,3-triazol-4-yl)imidazo[1,2-a]pyridine derivatives that activate CAR at nanomolar levels without triggering the related pregnane X receptor (PXR), […]
